Trinity Biotech Other Operating Income or Expenses 2010-2024 | TRIB
Trinity Biotech other operating income or expenses from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
Trinity Biotech Annual Other Operating Income or Expenses (Millions of US $) |
2023 |
$-11 |
2022 |
$-5 |
2021 |
$-2 |
2020 |
$-16 |
2019 |
$-24 |
2018 |
$-27 |
2017 |
$0 |
2016 |
$0 |
2015 |
$0 |
2014 |
$0 |
2013 |
$1 |
2012 |
$0 |
2011 |
$0 |
2010 |
$0 |
2009 |
$0 |
Trinity Biotech Quarterly Other Operating Income or Expenses (Millions of US $) |
2024-09-30 |
|
2024-06-30 |
$0 |
2024-03-31 |
$0 |
2023-12-31 |
$0 |
2023-09-30 |
$0 |
2023-06-30 |
$-11 |
2023-03-31 |
|
2022-12-31 |
$-3 |
2022-09-30 |
$-2 |
2022-06-30 |
$-1 |
2022-03-31 |
$0 |
2021-12-31 |
$0 |
2021-09-30 |
$1 |
2021-06-30 |
$-3 |
2021-03-31 |
$0 |
2020-12-31 |
$-16 |
2020-09-30 |
$0 |
2020-06-30 |
$0 |
2020-03-31 |
$0 |
2019-12-31 |
$-24 |
2019-09-30 |
$0 |
2019-06-30 |
$0 |
2019-03-31 |
$0 |
2018-12-31 |
$-27 |
2018-09-30 |
$0 |
2018-06-30 |
$0 |
2018-03-31 |
$0 |
2017-12-31 |
$0 |
2017-09-30 |
$0 |
2017-06-30 |
$0 |
2017-03-31 |
$0 |
2016-12-31 |
$0 |
2016-09-30 |
$0 |
2016-06-30 |
$0 |
2016-03-31 |
$0 |
2015-12-31 |
$0 |
2015-09-30 |
$0 |
2015-06-30 |
$0 |
2015-03-31 |
$0 |
2014-12-31 |
|
2014-09-30 |
|
2014-06-30 |
|
2014-03-31 |
|
2013-12-31 |
|
2013-09-30 |
|
2013-06-30 |
|
2013-03-31 |
|
2012-12-31 |
|
2012-09-30 |
|
2012-06-30 |
|
2012-03-31 |
|
2011-12-31 |
|
2011-09-30 |
|
2011-06-30 |
|
2011-03-31 |
|
2010-12-31 |
|
2010-09-30 |
|
2010-06-30 |
|
2010-03-31 |
|
2009-12-31 |
|
2009-09-30 |
|
2009-06-30 |
|
2009-03-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED PRODUCTS |
$0.014B |
$0.057B |
Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.
|